ProfileGDS5678 / 1439074_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 83% 82% 82% 80% 81% 85% 86% 83% 83% 82% 84% 82% 83% 83% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.0198983
GSM967853U87-EV human glioblastoma xenograft - Control 26.0037882
GSM967854U87-EV human glioblastoma xenograft - Control 35.9672282
GSM967855U87-EV human glioblastoma xenograft - Control 45.7916980
GSM967856U87-EV human glioblastoma xenograft - Control 55.8730181
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.1182185
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.2989386
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.0206883
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.0388783
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.0040382
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.2656684
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.9899882
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.0795183
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.9942383